Skip to main content

Advertisement

SpringerLink
Log in

Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany

  • Original paper
  • Published:
The European Journal of Health Economics Aims and scope Submit manuscript

Abstract

Patients with acute coronary syndrome without ST-segment elevation receiving clopidogrel in addition to acetylsalicylic acid (ASA) showed a 20% risk reduction in comparison to patients receiving ASA monotherapy (CURE trial). Economic models for assessing the impact on costs exist for several countries but not for Germany on a long-term basis. The objective of this model adaptation is to assess the long-term economic impact of clopidogrel taken in addition to ASA in Germany. A Markov model with six states [at risk, first year with stroke, following years with stroke, first year with new myocardial infarction (MI), following years with MI, and death] was adapted for Germany. Model outcome was life-years saved. Effects of 1-year treatment were calculated based on the CURE trial. Resource use for the different health states was based on published data, which included costs for drugs, outpatient care, hospitalization, rehabilitation and nursing. Risk data for MI and stroke were based on Swedish data and validated for the German adaptation. The model calculates lifetime costs and survival length. Costs were estimated from the payers’ perspective. A series of one-way sensitivity analyses was conducted (follow-up costs, discount rates). The Markov analysis predicts a survival of 8.89 years in the placebo treatment group and 9.02 years in the clopidogrel treatment group. The cumulated costs were €8,548 and €8,953, respectively. The incremental cost-effectiveness ratio (ICER) was €3,113 for each life-year saved. The model was robust regarding variations in key parameters in the sensitivity analysis, resulting in a range of ICER from €1,338 to €9,322. Our results are in line with the results for other healthcare systems. Adding clopidogrel to ASA for patients with acute coronary syndrome without ST-segment elevation generated an additional life-year saved at a comparably low value of €3,113. One-year treatment with clopidogrel is a cost-effective treatment option in patients with acute coronary syndrome from the perspective of a third-party payer in Germany.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Notes

  1. €1 = $1.2566 (June 21, 2006)

  2. £1 = €0.688 (February 10, 2005)

References

  1. Statistisches Bundesamt. Datenreport 2004 - Zahlen und Fakten für die Bundesrepublik Deutschland. Schriftenreihe Band 440. Bonn 2004

  2. Statistisches Bundesamt. http://www.destatis.de. (November 2004)

  3. Gesundheitsberichtserstattung des Bundes 2004 [Federal Health Report]. http://www.gbe-bund.de (September 2004)

  4. Klepzig, H., Krobot, K., Flettner, R., Winten, G., Zeiher, A.M.: Determinanten der Behandlungskosten der instabilen Angina pectoris. Z. Kardiol. 88, 261–269 (1999)

    Article  Google Scholar 

  5. Klever-Deichert, G., Hinzpeter, B., Hunsche, E., Lauterbach, K.W.: Costs of coronary heart diseases over the remaining life time in coronary heart disease cases--an analysis of the current status of coronary heart disease cases in Germany from the social perspective. Z. Kardiol. 88(12), 991–1000 (1999)

    Article  Google Scholar 

  6. Weimar, C., Weber, C., Wagner, M., Busse, O., Haberl, R.L., Lauterbach, K.W., Diener, H.C.: On behalf of the German Stroke Data Bank Collaborators. Management pattern and health care use after intracerebral hemorrhage. A cost-of-illness study from a societal perspective in Germany. Cerebrovasc. Dis. 15, 29–36 (2003)

    Article  Google Scholar 

  7. Brüggenjürgen, B., Rupprecht, H.J., Willich, S.N., Spannagl, M., Ehlken, B., Smala, A., Berger, K., Diener, H.C.: Cost of atherothrombotic diseases—myocardial infarction (MI), ischaemic stroke (IS) and peripheral arterial occlusive disease (PAD)—in Germany. J. Public Health 13(4), 216–224 (2005)

    Article  Google Scholar 

  8. The Clopidogrel In Unstable Angina To Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST segment elevation. N. Engl. J. Med. 345(7):494–502 (2001)

    Article  Google Scholar 

  9. Lindgren, P., Jonsson, B., Yusuf, S.: Cost-effectiveness of clopidogrel in acute coronary syndrome in Sweden: a long-term model based on the CURE trial. J. Intern. Med. 255(5), 562–570 (2004)

    Article  Google Scholar 

  10. Brüggenjürgen, B., Ehlken, B., Willich, S.: Kosteneffektivität von Clopidogrel bei zusätzlicher Gabe zu Acetylsalicylsäure (ASS) vs. ASS Monotherapie in Deutschland auf der Basis der CURE-Studie. Pharmacoecon. German Res. Articles 1(1), 15–24 (2003)

    Google Scholar 

  11. Sonnenberg, F.A., Beck, R.: Markov models in medical decision making: a practical guide. Med. Dec. Making. 13(4), 322–338 (1993)

    Article  Google Scholar 

  12. Fischer, F., Schiele, R., Zahn, R., Schneider, S., Wagner, S., Senges, J.: Comparison of acute myocardial infarct in the old and new lands of unified Germany, 1996–1998. Data of the myocardial infarct register (MIR). Dtsch. Med. Wochenschr. 125(40), 1181–1185 (2000)

    Article  Google Scholar 

  13. Berliner Herzinfarktregister. Ergebnisse des BHIR 1999–2001 [Myocardial Infarct Register Berlin]. http://www.herzinfarktregister.de/fakten (June 2004)

  14. Heuschmann, P.U., Kolominsky-Rabas, P.L., Misselwitz, B., Hermanek, P., Leffmann, C., Von Reutern, G.M., Lachenmeyer, L., Bucker-Nott, H.J., Berger, K.: Factors influencing duration of hospitalization after stroke in Germany. Dtsch. Med. Wochenschr. 129(7), 299–304 (2004)

    Article  Google Scholar 

  15. Grau, A., Weimar, C., Buggle Heinrich, A., Goertler, M., Neumaier, S., Glahn, J., Brandt, T., Hacke, W., Diener, C.: Risk factors, outcome and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke 32, 2559–2566 (2001)

    Article  Google Scholar 

  16. Rote Liste: Arzneimittelverzeichnis für Deutschland. Tariff list for drugs in Germany. Editio Cantor Verlag, Aulendorf (2005)

  17. Hannoveraner Konsens Gruppe: Dt. Empfehlungen zur gesundheitsökonomischen Evaluation–Revidierte Fassung des Hannoveraner Konsens. Gesundheitsökon. Qualitätsmanage. 4:A62–A65 (1999)

    Google Scholar 

  18. Lindgren, P., Jonsson, B., Spiesser, J., Carita, P., Gabriel, S.: Short and long term cost effectiveness analysis of clopidogrel in patients with acute coronary syndrome without ST-segment elevation (ACS) in Scandinavian countries. (Podium presentation at ISPOR 2003 in Barcelona). Value in Health. 6(6), 621 (2003)

    Google Scholar 

  19. Frei, A., Lindgren, P., Meiner, B.: Cost-effectiveness of clopidogrel in patients with acute coronary syndrome in Switzerland. Kardiovaskuläre Medizin. 7, 174–180 (2004)

    Google Scholar 

  20. Schwarz, B., Lindgren, P., Nanz, S.: Die Langzeit-Kosteneffektivität von Clopidogrel zusätzlich zu Azetylsalizylsäure bei Patienten mit akutem Koronarsyndrom ohne ST-Streckenhebung im österreichischen Gesundheitssystem. Pharmacoeconomics–German Research Articles 2(1), 31–41 (2004)

    Google Scholar 

  21. Weintraub, W.S., Mahoney, E.M., Lamy, A., Culler, S., Yuan, Y., Caro, J., Gabriel, S., Yusuf, S.: On behalf of the CURE study investigators. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. JACC. 45(6), 838–845 (2005)

    Google Scholar 

  22. Silber, S., Mahn, M.: Sekundärprophylaxe mit Clopidogrel bei Patienten mit klinisch manifester Atherothrombose in der täglichen hausärztlichen Praxis. Perfusion. 17, 178–184 (2004)

    Google Scholar 

  23. Schleinitz, M.D., Heidenreich, P.A.: A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. Ann. Intern. Med. 142(4):251–259 (2005)

    Google Scholar 

  24. Eichler, H.G., Kong, S.X., Gerth, W.C., Mavros, P., Jönsson, B.: Use of cost-effectiveness analysis in health care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value in Health 7(5), 518–528 (2004)

    Article  Google Scholar 

  25. Towse, A., Pritchard, C.: Does NICE have a threshold? An external view. In: Towse, A., Pritchard, C., Devlin, N. (eds.) Cost-effectiveness Thresholds. Economic and Ethical Issues. King’s Fund and Office of Health Economics, London (2002)

  26. Tengs, T., Adams, M., Pliskin, J., et al.: Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal. 15:369–390 (1995)

    Article  Google Scholar 

  27. Garber, A.M., Phelps, C.E.: Economic foundations of cost-effectiveness analysis. J. Health Econ. 16(1), 1–31 (1997)

    Article  Google Scholar 

  28. Chapman, R.H., Berger, M., Weinstein, M.C., Weeks, J.C., Goldie, S., Neumann, P.J.: When does quality-adjusting life-years matter in cost-effectiveness analysis? Health Econ. 13(5):429–436 (2004)

    Article  Google Scholar 

  29. Robberstad, B.: QALYs vs. DALYs vs LYs gained: What are the differences, and what difference do they make for health care priority setting? Norsk Epidemiol. 15(2), 183–191 (2005)

    Google Scholar 

  30. Troche, C.J., Tacke, J., Hinzpeter, B., Danner, M., Lauterbach, K.W: Cost-effectiveness of primary and secondary prevention in cardiovascular diseases. Eur. Heart J. 19(Supp C), C59–C65 (1998)

    Google Scholar 

  31. Schädlich, P.H., Brecht, J.G., Rangoonwala, B., Huppertz, E.: Cost effectiveness of Ramipril in patients at high risk for cardiovascular events–Economic evaluation of the heart outcomes prevention evaluation (HOPE) study for Germany from the perspective of statutory health insurance. Pharmacoeconomics 22, 955–973 (2004)

    Article  Google Scholar 

  32. WHO Commission on Macroeconomics and Health: Macroeconomics and Health: Investing in Health for Economic Development. Report of the Commission on Macroeconomics and Health. World Health Organization, Geneva (2001)

  33. Murray, C.J., Evans, D.B., Acharya, A., Baltussen, R.M.: Development of WHO guidelines on generalised cost-effectiveness analysis. Health Econ. 9(3), 235–251 (2000)

    Article  Google Scholar 

  34. OECD. http://www.oecd. org (February 2005)

Download references

Acknowledgements

The study was financially supported by Aventis Pharma Deutschland—ein Unternehmen der sanofi-aventis Gruppe, Berlin, Germany.

Author information

Authors and Affiliations

  1. Institute for Social Medicine, Epidemiology and Health Economics, Charité—Universitätsmedizin Berlin, Germany Luisenstr. 57, 10098, Berlin, Germany

    B. Brüggenjürgen & S. N. Willich

  2. Alpha Care Management and Research in Health Care Systems, Celle, Germany

    B. Brüggenjürgen

  3. Stockholm Health Economics, Stockholm, Sweden

    P. Lindgren

  4. Medical Economics Research Group (MERG), Munich, Germany

    B. Ehlken

  5. II. Medizinische Klinik, GPR Klinikum Rüsselsheim, Bebelstr. 59, 65428, Rüsselsheim, Germany

    H.-J. Rupprecht

Authors
  1. B. Brüggenjürgen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Lindgren
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Ehlken
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H.-J. Rupprecht
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. N. Willich
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B. Brüggenjürgen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brüggenjürgen, B., Lindgren, P., Ehlken, B. et al. Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany. Eur J Health Econ 8, 51–57 (2007). https://doi.org/10.1007/s10198-006-0006-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10198-006-0006-5

Keywords

JEL Classification

Search

Navigation